A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL: Intismeran autogene
BIOLOGICAL: Pembrolizumab
OTHER: Placebo

Sponsor

Merck Sharp & Dohme LLC